<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A variety of <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesions</z:e>, including <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, <z:mp ids='MP_0003269'>colonic polyps</z:mp>, <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, primary sclerosing <z:mp ids='MP_0003254'>cholangitis</z:mp>, intraductal mucin secreting <z:e sem="disease" ids="C0205875" disease_type="Neoplastic Process" abbrv="">papillomatosis</z:e> are now well recognized and accessible to direct endoscopic assessment and biopsy or brushing </plain></SENT>
<SENT sid="1" pm="."><plain>This review emphasizes the potential usefulness of genetic markers, in particular Ki-ras oncogene and p53 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene mutations, in the endoscopic surveillance of these <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant conditions</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The adjunction of Ki-ras and p53 assays in material collected during endoscopic procedures may help the clinician detect earlier and with a higher accuracy <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
</text></document>